Astellas Pharma: first half revenue of ¥1,270.86B and FY2027 outlook updated
FROM THE WIRE · SEEKINGALPHA.COM
* Astellas Pharma ADR press release [https://www.astellas.com/content/dam/astellas-com/global/en/confidential-documents/financial-results/2q2026_en.pdf] (ALPMY [https://seekingalpha.com/symbol/ALPMY]): 1H GAAP EPS of ¥134.47. * Revenue of ¥1,270.86B (+23.4% Y/Y).…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: neutralFirst-half results of a large drugmaker with an updated outlook, relevant for the biotech sector.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Astellas reported first-half GAAP EPS per ADR of ¥134.47.
- 02Revenue reached ¥1,270.86B, up 23.4% year over year.
- 03The company updated its outlook for fiscal year FY2027.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets